Juniper Biomedical – a medical device company that is focused on developing solutions that treat pelvic health disorders like incontinence using their unique neuromodulation micro-implant – announced that it has completed an oversubscribed $2 million seed funding round and also has been awarded $1 million through the NIH Common Fund as a winner of the NIH SPARC Neuromod Prize, a competition designed to accelerate the development of targeted neuromodulation therapies.
Auroral Holdings led this funding round, which included participation from Atma Capital, Hub Angels, Beacon Angels, and other private investors. This funding round will enable Juniper Biomedical to complete several development and commercialization milestones for its neuromodulation technology platform. The company’s first application will offer long-term precision therapy for patients with mixed urinary incontinence (MUI), which affects nearly one in three women.
Juniper Biomedical recently accelerated and has strong momentum, achieving several important preclinical and clinical milestones. The new funding will drive the company’s expansion plans.
KEY QUOTES:
“We are thrilled to have the support and confidence of our investors and NIH as we embark on the next phase of our journey to offer patients better care options. Our team will leverage these new funds to accelerate the development of transformative solutions for multiple care gaps in pelvic health.”
– David Constantine, Co-Founder and CEO of Juniper Biomedical
“We believe that Juniper Biomedical has tremendous potential for growth and disruption in pelvic health in the historically underserved patient populations. We are excited to partner with the company and look forward to supporting the team’s vision and innovation.”
– Larry Derose, founder of Auroral Holdings
